- Home
- MRM vs NCNA Comparison
MRM vs NCNA Comparison
Compare MRM & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | NCNA |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 13.8M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MRM | NCNA |
|---|---|---|
| Price | $1.70 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 97.3K | 83.4K |
| Earning Date | 05-22-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.25 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $2.78 |
| 52 Week High | $4.45 | $268.00 |
Technical Indicators
Market Signals| Indicator | MRM | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 42.80 |
| Support Level | $1.69 | $3.14 |
| Resistance Level | $1.78 | $3.50 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.94 | 26.12 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.